ChromaDex to Present at Canaccord Genuity’s 44th Annual Growth Conference
ChromaDex Corp. (NASDAQ:CDXC), a leader in NAD+ research and healthy aging, announces its participation in Canaccord Genuity's 44th Annual Growth Conference from August 13-15, 2024, in Boston. CEO Rob Fried and Interim CFO James Lee will present on August 14 and conduct one-on-one meetings throughout the event.
This prestigious conference, a 44-year cornerstone for industry leaders and investors, provides ChromaDex an opportunity to showcase its latest developments, strategic initiatives, and growth prospects. Interested parties can arrange meetings through the conference website or their CG representative.
ChromaDex's involvement underscores its commitment to engaging with investors and industry experts, potentially impacting its market position and future growth strategies in the healthy aging sector.
ChromaDex Corp. (NASDAQ:CDXC), un leader nella ricerca sul NAD+ e sull'invecchiamento sano, annuncia la sua partecipazione alla 44ª Conferenza Annuale sulla Crescita di Canaccord Genuity che si svolgerà dal 13 al 15 agosto 2024 a Boston. Il CEO Rob Fried e il CFO ad interim James Lee presenteranno il 14 agosto e svolgeranno incontri individuali durante l'evento.
Questa prestigiosa conferenza, un punto di riferimento per i leader del settore e gli investitori da 44 anni, offre a ChromaDex un'opportunità per mostrare i suoi ultimi sviluppi, iniziative strategiche e prospettive di crescita. Le parti interessate possono organizzare incontri tramite il sito web della conferenza o tramite il loro rappresentante CG.
Il coinvolgimento di ChromaDex sottolinea il suo impegno a interagire con investitori ed esperti del settore, potenzialmente influenzando la sua posizione di mercato e le strategie di crescita future nel settore dell'invecchiamento sano.
ChromaDex Corp. (NASDAQ:CDXC), un líder en la investigación sobre NAD+ y el envejecimiento saludable, anuncia su participación en la 44ª Conferencia Anual de Crecimiento de Canaccord Genuity que se llevará a cabo del 13 al 15 de agosto de 2024 en Boston. El CEO Rob Fried y el CFO interino James Lee presentarán el 14 de agosto y realizarán reuniones uno a uno durante el evento.
Esta prestigiosa conferencia, un pilar durante 44 años para los líderes de la industria y los inversores, le brinda a ChromaDex la oportunidad de mostrar sus últimos desarrollos, iniciativas estratégicas y perspectivas de crecimiento. Las partes interesadas pueden organizar reuniones a través del sitio web de la conferencia o de su representante de CG.
La participación de ChromaDex resalta su compromiso de relacionarse con inversores y expertos de la industria, lo que puede impactar su posición en el mercado y las estrategias de crecimiento futuro en el sector del envejecimiento saludable.
크로마덱스 주식회사 (NASDAQ:CDXC), NAD+ 연구 및 건강한 노화의 선두주자가, 2024년 8월 13일부터 15일까지 보스턴에서 열리는 캐나다르드 제뉴이티 제44회 연례 성장 컨퍼런스에 참가한다고 발표했습니다. CEO 롭 프리드와 임시 CFO 제임스 리가 8월 14일에 발표를 하고 이벤트 동안 1:1 미팅을 진행합니다.
이 권위 있는 컨퍼런스는 44년 동안 산업 리더와 투자자들을 위한 주춧돌 역할을 하며, 크로마덱스에게는 최신 개발, 전략적 이니셔티브 및 성장 전망을 선보일 기회를 제공합니다. 관심 있는 분들은 컨퍼런스 웹사이트나 CG 대표를 통해 미팅을 조정할 수 있습니다.
크로마덱스의 참여는 투자자 및 산업 전문가와의 소통을 다짐하는 것이며, 이는 건강한 노화 분야에서의 시장 위치와 향후 성장 전략에 영향을 미칠 수 있습니다.
ChromaDex Corp. (NASDAQ:CDXC), un leader dans la recherche sur le NAD+ et le vieillissement en bonne santé, annonce sa participation à la 44ème Conférence Annuelle de Croissance de Canaccord Genuity qui se déroulera du 13 au 15 août 2024 à Boston. Le PDG Rob Fried et le CFO par intérim James Lee présenteront le 14 août et réaliseront des réunions en tête-à-tête tout au long de l'événement.
Cette conférence prestigieuse, qui est un pilier depuis 44 ans pour les leaders de l'industrie et les investisseurs, offre à ChromaDex l'opportunité de présenter ses derniers développements, initiatives stratégiques et perspectives de croissance. Les parties intéressées peuvent organiser des réunions via le site web de la conférence ou leur représentant CG.
La participation de ChromaDex souligne son engagement à interagir avec les investisseurs et les experts de l'industrie, ce qui pourrait influer sur sa position sur le marché et ses stratégies de croissance futures dans le secteur du vieillissement en bonne santé.
ChromaDex Corp. (NASDAQ:CDXC), ein führendes Unternehmen in der NAD+-Forschung und im Bereich gesundes Altern, gibt seine Teilnahme an der 44. jährlichen Wachstums-konferenz von Canaccord Genuity vom 13. bis 15. August 2024 in Boston bekannt. CEO Rob Fried und Interim-CFO James Lee werden am 14. August präsentieren und während der Veranstaltung Einzelgespräche führen.
Diese renommierte Konferenz, die seit 44 Jahren ein Grundpfeiler für Branchenführer und Investoren ist, bietet ChromaDex die Möglichkeit, seine neuesten Entwicklungen, strategischen Initiativen und Wachstumsperspektiven vorzustellen. Interessierte Parteien können über die Website der Konferenz oder ihren CG-Vertreter Meetings arrangieren.
Die Beteiligung von ChromaDex unterstreicht sein Engagement für den Austausch mit Investoren und Branchenexperten, was potenziell Einfluss auf seine Markposition und zukünftige Wachstumsstrategien im Bereich gesundes Altern haben könnte.
- None.
- None.
For 44 years, Canaccord Genuity’s Annual Growth Conference has been a cornerstone for industry leaders and investors, fostering valuable connections and insights.
Mr. Fried and Mr. Lee will lead a presentation on Wednesday, August 14, and conduct one-on-one meetings throughout the conference to discuss ChromaDex’s latest developments, strategic initiatives, and growth opportunities with investors and industry experts.
For more information about ChromaDex’s participation or to arrange a meeting with Mr. Fried and Mr. Lee, please visit the conference website here, or contact your CG representative.
For additional information on ChromaDex, visit www.chromadex.com.
About ChromaDex:
ChromaDex Corp. (NASDAQ:CDXC) is the global authority on nicotinamide adenine dinucleotide (NAD+), with a focus on the science of healthy aging. The ChromaDex team, comprised of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full potential of NAD+. A vital coenzyme found in every cell of the human body, NAD+ declines with age and exposure to other everyday stressors. NAD+ depletion is a contributor to age-related changes in health and vitality.
Setting the benchmark as the gold standard in scientific rigor, safety, quality, and transparency, ChromaDex is the innovator behind its clinically proven flagship ingredient, Niagen (patented nicotinamide riboside, or NR), the most efficient and superior-quality NAD+ booster available.
Niagen is the active ingredient in ChromaDex’s consumer products, sold as the brand Tru Niagen®, the number one healthy-aging NAD+ supplement in
ChromaDex’s robust patent portfolio protects NR and other NAD+ precursors. ChromaDex maintains a website at www.chromadex.com, to which ChromaDex regularly publishes copies of its press releases, news, and financial information.
†Based on the top-selling dietary supplement brands by revenue per the largest
View source version on businesswire.com: https://www.businesswire.com/news/home/20240805054867/en/
ChromaDex Media Contact:
Kendall Knysch, Senior Director of Media Relations & Partnerships
310-388-6706 ext. 689
kendall.knysch@chromadex.com
ChromaDex Investor Relations Contact:
Ben Shamsian
Lytham Partners
646-829-9701
shamsian@lythampartners.com
Source: ChromaDex Corporation
FAQ
When is ChromaDex (CDXC) presenting at Canaccord Genuity's Growth Conference?
Who will represent ChromaDex (CDXC) at the Canaccord Genuity conference?
Where is Canaccord Genuity's 44th Annual Growth Conference being held?
What will ChromaDex (CDXC) discuss at the Canaccord Genuity conference?
How can investors arrange meetings with ChromaDex (CDXC) at the conference?
